Chlorhexidine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1976
- First approval year
- 1976
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Chlorhexidine
- Molecular weight
- 505.46
- Structure (SMILES)
- N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1
- avagard
- Avagard
- chlorhexadine
- Chlorhexadine
- chlorhexidine
- Chlorhexidine
- CHLORHEXIDINE [HSDB]
- chlorhexidine [INN]
- CHLORHEXIDINE [MART.]
- CHLORHEXIDINE [MI]
- CHLORHEXIDINE [USP-RS]
- CHLORHEXIDINE [VANDF]
- Chlorhexidine [WHO-DD]
- chlorhexidine hsdb
- chlorhexidine inn
- chlorhexidine mart
- chlorhexidine mi
- chlorhexidine usp rs
- chlorhexidine vandf
- chlorhexidine who dd
- clorhexidina
- Clorhexidina
- dentisept
- Dentisept
- merfen incolore
And 1 more, listed on the interactive page.
- CAS registry numbers
- 55-56-1
- ChEMBL ID
- CHEMBL790
- InChIKey
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N
- FDA ingredient codes (UNII)
- R4KO0DY52L
- A01AB03
- B05CA02
- D08AC02
- D08AC52
- D09AA12
- R02AA05
- S01AX09
- S02AA09
- S03AA04
Sources for recorded values
- 2713
- 5353524
- 5360566
- 9552079
- 88536661
- 2358
- 133054
- Applicant
- MOLNLYCKE HLTH
- Approval date
- 17 Sept 1976
- Application number
- NDA017768
- First in class
- No
- Orphan designation
- No
- Availability
- Over the counter
- United States (FDA)
- Approved
- Pharmacology name
- chlorhexidine
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- TAS2R2
- Gene symbol
- TAS2R2
- Protein identifier
- Q50KZ9
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Periodontitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Bacterial Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Bacteremia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003033
- Subject identifier
- D016470
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Dental Caries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003819
- Subject identifier
- D003731
- Condition
- Staphylococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005681
- Subject identifier
- D013203
- Condition
- Communicable Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Acanthamoeba Keratitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007126
- Subject identifier
- D015823
- Condition
- Peri-Implantitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001390
- Subject identifier
- D057873
- Condition
- Periodontal Pocket
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001393
- Subject identifier
- D010514
- Condition
- Diabetic Foot
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001459
- Subject identifier
- D017719
- Condition
- Pneumonia, Ventilator-Associated
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001865
- Subject identifier
- D053717
- Condition
- Eye Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001888
- Subject identifier
- D015817
- Condition
- Stomatitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001904
- Subject identifier
- D013280
- Condition
- Neonatal Sepsis
- Highest recorded phase
- 2
- Condition identifier
- HP:0040187
- Subject identifier
- D000071074
- Condition
- Neutropenia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001475
- Subject identifier
- D009503
- Condition
- Pharyngitis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002258
- Subject identifier
- D010612
- Condition
- Gingivitis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002508
- Subject identifier
- D005891
- Condition
- Periodontal Diseases
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002635
- Subject identifier
- D010510
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000649
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0003033
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003819
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005681
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005741
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007126
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001390
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001390
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001393
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001459
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001888
- Condition identifier
- EFO_1001888
- Highest recorded phase
- 4
- Condition identifier
- EFO_1001904
- Highest recorded phase
- 2
- Condition identifier
- HP_0000225
- Condition identifier
- HP_0000822
- Condition identifier
- HP_0011947
- Highest recorded phase
- 2
- Condition identifier
- HP_0040187
- Highest recorded phase
- 2
- Condition identifier
- HP_0100806
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000984
- Condition identifier
- MONDO_0001475
- Highest recorded phase
- 3
And 15 more, listed on the interactive page.
- Warning
- Withdrawn
- Effect
- dermatological toxicity
- Description
- associated with chemical and thermal burns
- Year
- 1984
- Country
- United States
- Condition
- caustic injury
- Warning
- Withdrawn
- Effect
- dermatological toxicity
- Description
- associated with chemical and thermal burns
- Year
- 1984
- Country
- United States
- Condition
- thermal burn
- Event
- abdominal discomfort
- Reports
- 173
- Reporting signal score
- 417.242
- Event
- abdominal pain upper
- Reports
- 128
- Reporting signal score
- 232.177
- Event
- abdominal wound dehiscence
- Reports
- 5
- Reporting signal score
- 22.1031
- Event
- acanthamoeba keratitis
- Reports
- 4
- Reporting signal score
- 24.3854
- Event
- allergy to chemicals
- Reports
- 10
- Reporting signal score
- 43.846
- Event
- alopecia
- Reports
- 165
- Reporting signal score
- 386.636
- Event
- anaphylactic reaction
- Reports
- 125
- Reporting signal score
- 302.29
- Event
- anaphylactic shock
- Reports
- 15
- Reporting signal score
- 18.5406
- Event
- anti-cyclic citrullinated peptide antibody
- Reports
- 3
- Reporting signal score
- 14.3174
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 153
- Reporting signal score
- 814.425
- Event
- arthralgia
- Reports
- 298
- Reporting signal score
- 576.426
- Event
- arthropathy
- Reports
- 169
- Reporting signal score
- 522.231
- Event
- aspartate aminotransferase increased
- Reports
- 19
- Reporting signal score
- 11.2089
- Event
- asthenia
- Reports
- 125
- Reporting signal score
- 134.842
- Event
- asthenopia
- Reports
- 18
- Reporting signal score
- 67.6161
- Event
- back pain
- Reports
- 113
- Reporting signal score
- 167.094
- Event
- blister
- Reports
- 313
- Reporting signal score
- 1,224.68
- Event
- blood alkaline phosphatase increased
- Reports
- 18
- Reporting signal score
- 21.7274
- Event
- blood cholesterol increased
- Reports
- 15
- Reporting signal score
- 17.1766
- Event
- blood lactate dehydrogenase increased
- Reports
- 19
- Reporting signal score
- 33.3358
- Event
- blood pressure diastolic abnormal
- Reports
- 8
- Reporting signal score
- 26.7052
- Event
- blood pressure diastolic increased
- Reports
- 8
- Reporting signal score
- 19.9422
- Event
- blood pressure systolic abnormal
- Reports
- 8
- Reporting signal score
- 26.911
- Event
- blood pressure systolic increased
- Reports
- 10
- Reporting signal score
- 13.2133
- Event
- body temperature increased
- Reports
- 115
- Reporting signal score
- 406.779
And 111 more, listed on the interactive page.
- NCT00067340
- NCT00357877
- NCT03669224
- NCT03684993
- NCT03773094
- NCT03855527
- NCT04679558
- NCT00290290
- NCT00608959
- NCT01989416
- NCT02219776
- NCT02279381
- NCT02396329
- NCT03640507
- NCT03757143
- NCT03838575
- NCT03853200
- NCT00425451
- NCT01040286
- NCT03700788
- NCT03836781
- NCT00560599
- NCT00597688
- NCT01083407
- NCT00707902
And 23 more, listed on the interactive page.
- Dose
- 2mL
- Route
- Topical
- How often
- Once daily
- Allow to dry before donning gloves
- Apply to clean, dry hands and nails
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 10
- Polar surface area
- 167.58
- Calculated partition coefficient (ALogP)
- 4.18
- Calculated partition coefficient (XLogP)
- 0.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 9
- Heavy atoms
- 34
- Molecular formula
- C22H30Cl2N10
- Monoisotopic mass
- 504.2031964
- Natural product
- Yes
- Recorded assays
- 413
- Active assays
- 305
- Confirmatory
- Other
- Screening
- Summary
- Anti-Infective Agents, Local
Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects.
- Disinfectants
Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley's Condensed Chemical Dictionary, 11th ed)
- Mouthwashes
Solutions for rinsing the mouth, possessing cleansing, germicidal, or palliative properties. (From Boucher's Clinical Dental Terminology, 4th ed)
- Anti-Infective Agents, Local
- Disinfectants
- Mouthwashes
Related records
Trials (253)
- "Clinical Trials to Enhance Elders' Oral Health" ("TEETH")
- 0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia
- 0.2% Chlorhexidine vs MicroRepair ABX in Gingivitis
- 2% Chlorhexidine (CHX) vs CaOH2 (CH) Calcium Hydroxide Paste as an Intracanal Medicament
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects
- A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns
- A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases
- A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures
- A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection
- A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
- Active Oxygen Gel vs Chlorhexidine Gel in Stage II Grade B Periodontitis
- Alcoholic Chlorhexidine Compared to Povidone Iodine to Limit Perineural Catheter Colonisation
- Aloe Vera and Chlorhexidine Against Traumatic Oral Ulcers
- Animal-Assisted Visitation Program Chlorhexidine Trial
- Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide
- Antibacterial Effect and Substantivity of a New Chlorhexidine and Cymenol Gel on Oral Biofilm and Saliva
- Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs
- Antibacterial Effect of Guava Leaves Extract Mouthwash Compared to Chlorhexidine Mouthwash in High Caries Risk Patients
- Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique
- Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk
Approved for (1)
- Eye infectious disorder
In development for (20)
- Acanthamoeba keratitis Phase 2
- Bacterial infectious disease Phase 3
- Bacterial infectious disease with sepsis Phase 3
- Bacterial vaginosis Phase 2
- Chronic obstructive pulmonary disease Phase 2
- Chronic periodontitis Phase 2
- COVID-19 Phase 2
- Dental caries Phase 3
- Gingivitis Phase 3
- Infectious disease Phase 3
- Methicillin-resistant staphylococcus aureus infectious disease Phase 2
- Neonatal sepsis Phase 2
- Neutropenia Phase 3
- Non-small cell lung carcinoma Phase 2
- Periodontal disorder Phase 2
- Periodontitis Phase 3
- Pharyngitis Phase 3
- Pneumonia Phase 3
- Staphylococcus aureus infection Phase 3
- Stomatitis Phase 2
Other linked conditions (4)
- Enterococcus faecalis infection
- Hypertensive disorder
- Periapical periodontitis
- Thalassemia